Calypso Biotech is the third spin-off company from the EPP Fund. The company is developing antibody therapeutics against niche gastro-intestinal immune disorders, such as refractory celiac disease and Crohn`s Disease. Calypso Biotech is based in Geneva, Switzerland.
Dose-escalation study to evaluate safety, biological and early clinical effect of CALY-002 in healthy volunteers and patients with Celiac Disease and Eosinophilic Esophagitis
2017/03/29Calypso Biotech SA announced today that it has entered a global licensing and collaboration agreement with EA Pharma Co., Ltd. to develop CALY-001, a best-in-class anti-MMP-9 fully human monoclonal antibody.
